ReviewBlood reviews2021
The clinical implications of clonal hematopoiesis in hematopoietic cell transplantation.
Review in Blood reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.Transplantation and cellular therapy · 2024Guideline
- Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis.American journal of hematology · 2022Pooled it
- Cardio-Oncological Sequelae of Autologous Stem Cell Transplantation: Role of Clonal Hematopoiesis in Cardiovascular Risk.JACC. Advances · 2026Article
- Don't Cut the Cord: Why Umbilical Cord Blood Still Deserves a Place in Transplantation.International journal of immunogenetics · 2026Review
- Long-term tracking of haematopoietic clonal dynamics and mutations in non-human primate undergoing transplantation of lentivirally barcoded haematopoietic stem and progenitor cells.British journal of haematology · 2024Article
- Hemostasis and complement in allogeneic hematopoietic stem cell transplantation: clinical significance of two interactive systems.Bone marrow transplantation · 2024Review
- Influence of the Bone Marrow Microenvironment on Hematopoietic Stem Cell Behavior Post-Allogeneic Transplantation: Development of Clonal Hematopoiesis and Telomere Dynamics.International journal of molecular sciences · 2024Article
- International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.Bone marrow transplantation · 2024Review
- Cell of origin epigenetic priming determines susceptibility to Tet2 mutation.Nature communications · 2024Article
- Sickle cell disease and acute leukemia: one case report and an extensive review.Annals of hematology · 2023Review
- Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia.Cold Spring Harbor molecular case studies · 2023Article
- Clonal hematopoiesis, somatic mosaicism, and age-associated disease.Physiological reviews · 2023Review
- Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma.Blood reviews · 2022Review
- Clonal hematopoiesis: Mutation-specific adaptation to environmental change.Cell stem cell · 2022Review
- Germline risk of clonal haematopoiesis.Nature reviews. Genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 2 countries.
Funding
Abstract
Clonal hematopoiesis (CH) describes somatic mutations in hematopoietic stem and progenitor cells resulting in clonal expansion in individuals with no overt hematologic disease. Since CH increases in an age-related manner, understanding its role in hematopoietic cell transplantation (HCT) has become increasingly relevant to an aging transplant population. Multiple factors distinguish post-transplant hematopoiesis from unperturbed, steady-state hematopoiesis, including the influence of immunosuppressants, cytotoxic reagents, and marked proliferative stress, all of which may enhance or diminish the opportunity for clonal expansion. We reviewed the available clinical evidence on the consequences of CH at time of transplant in patients undergoing autologous HCT, and the impact of donor and recipient CH on allogeneic HCT outcomes. In the absence of evidence-based guidelines, we share our suggestions for managing donors and recipients found to have CH. Large-scale studies are needed to guide an evidence-based, uniform approach for the management of CH in the setting of HCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.